Long Term Survival and Quality of Life Following Transcatheter Aortic Valve Replacement in Nonagenarians.

Madanat, Luai; Allam, Mohamed; Khalili, Houman; Rabah, Andrew; Tariq, Rehan; Zamzam, Mazen; Rodés-Cabau, Josep; Pilgrim, Thomas; Okuno, Taishi; Elmariah, Sammy; Pibarot, Philippe; Abbas, Amr E (2024). Long Term Survival and Quality of Life Following Transcatheter Aortic Valve Replacement in Nonagenarians. The American journal of cardiology, 213, pp. 140-145. Elsevier 10.1016/j.amjcard.2023.12.031

Text 1-s2.0-S0002914923014157-main.pdf - Accepted Version Restricted to registered users only until 20 December 2024. Available under License Publisher holds Copyright. Download (1MB)

Transcatheter aortic valve replacement (TAVR) has emerged as a successful treatment option for severe aortic stenosis (AS). However, the long term outcomes of TAVR in nonagenarians is lacking. We aimed to examine the long-term mortality and quality-of-life in nonagenarians after TAVR. This is a multi-center retrospective analysis on patients with severe AS undergoing TAVR. Patients were divided into two groups: Nonagenarians (age ≥ 90 years) and age < 90 years. Kansas city cardiomyopathy questionnaires (KCCQ) and New York Heart Associated (NYHA) scores were compared pre- and post-TAVR. All-cause mortality was compared between both groups at 30 days, 1-year and 5-years post-TAVR using Cox-proportional hazard model. A total of 6896 patients were included, of which 591 were nonagenarians. Nonagenarians had a higher STS perioperative risk of mortality (8.1 ± 4.6% vs 5.4 ± 4.2%, p<0.001) pre-TAVR. Both groups were similar in baseline KCCQ and NYHA scores. At one year post-TAVR, there was no significant difference in improvement in the KCCQ overall score between age < 90 and nonagenarians (-4.76, 95% CI: -11.4 - 1.9, p = 0.161). Similarly, there was no statistically significant difference in improvement in NYHA class between the two groups at 1-year (OR: 1.07, 95% CI: 0.85 - 1.25), p = 0.526). The unadjusted 30-day (3.2% vs 2.7%; HR:1.11, 95% CI: 0.70-1.80, p=0.667) and 5-year (28.0% vs 26.6%, HR: 1.05, 95% CI:0.89-1.24, p=0.60) all-cause mortality were similar between the two groups. In conclusion, this study demonstrates an excellent long-term mortality rate at 5 years following TAVR in nonagenarians, comparable to patients younger than 90 years old. There is a significant and enduring improvement in functional status in nonagenarians, observed up to 1 year following TAVR.

Interest & Impact

Downloads

0 since deposited on 28 Dec 2023
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item